Abortion pill fight: Read the transcript of Texas court hearing on fate of mifepristone

Abortion pill fight: Read the transcript of Texas court hearing on fate of mifepristone


Abortion rights advocates gather in front of the J Marvin Jones Federal Building and Courthouse in Amarillo, Texas, on March 15, 2023.

Moises Avila | AFP | Getty Images

A federal judge in Texas heard arguments for the first time this week in a closely watched case challenging the Food and Drug Administration’s approval of mifepristone.

The hearing in Amarillo on Wednesday was open to the public but it was not livestreamed.

Judge Matthew Kacsmaryk of the U.S. Northern District of Texas in Amarillo heard four hours of arguments. The anti-abortion group that filed the lawsuit, the Alliance Defending Freedom, presented their case against the FDA first. They were followed by Justice Department attorneys defending the FDA and then the abortion pill maker Danco Laboratories.

The Alliance Defending Freedom argued that mifepristone is unsafe and the FDA did not properly follow its approval process when it cleared mifepristone for use in 2000. The Justice Department strongly disputed those claims, arguing the FDA used its congressionally authorized powers to approve a drug it determined is safe and effective.

Download a full copy of the hearing transcript here.

“This Court will issue an order and opinion as soon as possible,” Kacsmaryk said at the hearing’s conclusion.

Erik Baptist, the top attorney at Alliance Defending Freedom, told the judge that he has the authority to order the FDA to initiate its internal process to withdraw a drug from the market, but argued that such an action would be inappropriate in this case because it could take “many years.”

Instead, Baptist argued the court can “on its own accord” order the FDA to withdraw the drug from the market rather than relying on the agency to initiate its internal procedures to do so.

“Any relief that you grant, Your Honor, it must be complete. The scope of plaintiffs’–of this relief needs to be universal and nationwide,” Baptist told the judge.

Kacsmaryk asked Baptist to explain why the court has such “sweeping authority.” Baptist said the court has the power to “take whatever action to prevent harm.” The judge also asked Baptist if he could point to any other case of a court withdrawing a drug that’s been on the market for more than 20 years. 

“My answer to your question is, no, I can’t,” Baptist said, though he argued that this is because the FDA stonewalled previous petitions to pull mifepristone and impose tougher restrictions.

Julie Straus Harris, an attorney from the Justice Department, said the statute of limitations bars the plaintiffs from challenging the FDA’s approval of mifepristone in 2000. Harris argued that the public interest would be “irreparably injured” by an order pulling mifepristone from the market.

“An injunction would cause significant public harm, depriving patients and doctors of a safe and effective drug that has been on the market for more than two decades,” Harris said. She argued such an order would upend the status quo and harm patients, doctors and the pharmaceutical industry’s reliance on FDA drug approvals.

CNBC Health & Science

Read CNBC’s latest global health coverage:

Kacsmaryk sparked controversy prior to oral arguments after The Washington Post reported that he sought keep news of the hearing’s date quiet. Citing death threats and harassment, Kacsmaryk told attorneys involved in the case that “less advertisement is better” during a telephone conference call last week, according to a court transcript.

The court ultimately relented and shared the date on Monday after media outlets, including NBCUniversal News group of which CNBC is part, filed a letter criticizing the move as “unconstitutional.”

“The Court’s attempt to delay notice of and, therefore, limit the ability of members of the public, including the press, to attend Wednesday’s hearing is unconstitutional, and undermines the important values served by public access to judicial proceedings and court records,” wrote Peter Steffensen of Southern Methodist University’s Dedman School of Law on behalf of the media outlets.



Source

Moderna cuts high end of 2025 revenue outlook on vaccine shipment delay in U.K.
Health

Moderna cuts high end of 2025 revenue outlook on vaccine shipment delay in U.K.

Moderna logo is seen in Warsaw, Poland on April 9, 2025. Jakub Porzycki | Nurphoto | Getty Images Moderna on Friday lowered the high end of its 2025 revenue outlook due to a delay in vaccine shipments to the U.K., but beat Wall Street’s expectations for the second quarter as it works to cut costs. […]

Read More
Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days
Health

Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days

U.S. President Donald Trump, U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy, Jr., Dr. Mehmet Oz, Administrator for the Centers for Medicare & Medicaid Services, David Sacks, AI & Crypto Czar and Amy Gleason, Acting Administrator, Department of Government Efficiency (DOGE) attend the “Making Health Technology Great Again” event in the East Room […]

Read More
Eli Lilly’s Mounjaro shows heart health benefits in head-to-head trial with older diabetes drug Trulicity
Health

Eli Lilly’s Mounjaro shows heart health benefits in head-to-head trial with older diabetes drug Trulicity

Mounjaro manufactured by Eli Lilly and Company packaging is seen in this illustration photo taken in a pharmacy in Krakow, Poland on April 9, 2024. Nurphoto | Nurphoto | Getty Images Eli Lilly on Thursday said its blockbuster diabetes drug Mounjaro showed heart health benefits in a late-stage trial directly comparing it to the company’s […]

Read More